First human trial of novel vaccine targeting meningococcal B begins.
- Delonix BioWorks launches Phase 1 trial of vaccine DX-104.
- The vaccine targets meningococcal B infection.
- This trial marks a significant step in vaccine research.
Delonix BioWorks has announced the commencement of a Phase 1 clinical trial for its new meningococcal B outer membrane vesicle (OMV) vaccine, DX-104. This vaccine aims to enhance protection against meningococcal disease, a serious infection caused by Neisseria meningitidis. The trial is a critical step in evaluating the safety and immunogenicity of the vaccine in healthy adults.
The Phase 1 trial will assess the safety profile and immune response generated by DX-104 in participants. Meningococcal disease remains a significant health risk, and the development of an effective vaccine is essential for preventing outbreaks. The ongoing research aims to provide stronger immunity against this potentially life-threatening infection.
Delonix BioWorks is committed to advancing vaccine research to combat meningococcal infections. The initiation of this clinical trial signifies an important milestone in the company's efforts to deliver innovative solutions for public health challenges related to infectious diseases.
